These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34559824)

  • 21. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
    Irazabal MV; Abebe KZ; Bae KT; Perrone RD; Chapman AB; Schrier RW; Yu AS; Braun WE; Steinman TI; Harris PC; Flessner MF; Torres VE;
    Nephrol Dial Transplant; 2017 Nov; 32(11):1857-1865. PubMed ID: 27484667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
    Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD
    Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.
    Perico N; Ruggenenti P; Perna A; Caroli A; Trillini M; Sironi S; Pisani A; Riccio E; Imbriaco M; Dugo M; Morana G; Granata A; Figuera M; Gaspari F; Carrara F; Rubis N; Villa A; Gamba S; Prandini S; Cortinovis M; Remuzzi A; Remuzzi G;
    PLoS Med; 2019 Apr; 16(4):e1002777. PubMed ID: 30951521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
    Caroli A; Perico N; Perna A; Antiga L; Brambilla P; Pisani A; Visciano B; Imbriaco M; Messa P; Cerutti R; Dugo M; Cancian L; Buongiorno E; De Pascalis A; Gaspari F; Carrara F; Rubis N; Prandini S; Remuzzi A; Remuzzi G; Ruggenenti P;
    Lancet; 2013 Nov; 382(9903):1485-95. PubMed ID: 23972263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in Kidney and Liver Volumes in Patients With Autosomal Dominant Polycystic Kidney Disease Before and After Dialysis Initiation.
    Suwabe T; Ubara Y; Oba Y; Mizuno H; Ikuma D; Yamanouchi M; Sekine A; Tanaka K; Hasegawa E; Hoshino J; Sawa N
    Mayo Clin Proc Innov Qual Outcomes; 2023 Feb; 7(1):69-80. PubMed ID: 36712823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use.
    Mizuno H; Sekine A; Suwabe T; Ikuma D; Yamanouchi M; Hasegawa E; Sawa N; Ubara Y; Hoshino J
    PLoS One; 2022; 17(2):e0264065. PubMed ID: 35176098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.
    Pisani A; Sabbatini M; Imbriaco M; Riccio E; Rubis N; Prinster A; Perna A; Liuzzi R; Spinelli L; Santangelo M; Remuzzi G; Ruggenenti P;
    Clin Gastroenterol Hepatol; 2016 Jul; 14(7):1022-1030.e4. PubMed ID: 26844873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.
    Seliger SL; Abebe KZ; Hallows KR; Miskulin DC; Perrone RD; Watnick T; Bae KT
    Am J Nephrol; 2018; 47(5):352-360. PubMed ID: 29779024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic Targets in Polycystic Liver Disease.
    Masyuk TV; Masyuk AI; LaRusso NF
    Curr Drug Targets; 2017; 18(8):950-957. PubMed ID: 25915482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
    D'Agnolo HM; Kievit W; Takkenberg RB; Riaño I; Bujanda L; Neijenhuis MK; Brunenberg EJ; Beuers U; Banales JM; Drenth JP
    J Hepatol; 2016 Sep; 65(3):601-7. PubMed ID: 27212247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
    Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
    J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease.
    Riyahi S; Dev H; Blumenfeld JD; Rennert H; Yin X; Attari H; Barash I; Chicos I; Bobb W; Donahue S; Prince MR
    J Magn Reson Imaging; 2021 Feb; 53(2):564-576. PubMed ID: 32969110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.
    Brosnahan GM; Abebe KZ; Rahbari-Oskoui FF; Patterson CG; Bae KT; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Perrone RD; Steinman TI; Torres VE;
    Curr Hypertens Rev; 2017; 13(2):109-120. PubMed ID: 28460625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
    Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
    Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
    Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.
    Caroli A; Antiga L; Cafaro M; Fasolini G; Remuzzi A; Remuzzi G; Ruggenenti P
    Clin J Am Soc Nephrol; 2010 May; 5(5):783-9. PubMed ID: 20185596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease.
    van Gastel MDA; Edwards ME; Torres VE; Erickson BJ; Gansevoort RT; Kline TL
    J Am Soc Nephrol; 2019 Aug; 30(8):1514-1522. PubMed ID: 31270136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan.
    Higashihara E; Nutahara K; Okegawa T; Tanbo M; Mori H; Miyazaki I; Nitatori T; Kobayashi K
    Clin Exp Nephrol; 2015 Aug; 19(4):746-52. PubMed ID: 25351823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlations between renal function and the total kidney volume measured on imaging for autosomal dominant polycystic kidney disease: A systematic review and meta-analysis.
    Jo WR; Kim SH; Kim KW; Suh CH; Kim JK; Kim H; Lee JG; Oh WY; Choi SE; Pyo J
    Eur J Radiol; 2017 Oct; 95():56-65. PubMed ID: 28987699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Tsukamoto S; Urate S; Yamada T; Azushima K; Yamaji T; Kinguchi S; Uneda K; Kanaoka T; Wakui H; Tamura K
    Front Pharmacol; 2022; 13():885457. PubMed ID: 35662736
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.